IN8bio Inc

Research IN8bio Inc (INAB) on Bullrun: market cap USD 14.08M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerINAB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 14.08M
• Financial periodFY2025
• Net income-USD 19.44M

Valuation Snapshot

latest market cap is USD 14.08M.

About IN8bio Inc

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM;

Frequently asked questions

What is IN8bio Inc's market cap?

IN8bio Inc's market capitalization is USD 14.08M.

What does IN8bio Inc do?

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.